Piedmont Investment Advisors Inc. Buys 211 Shares of Illumina, Inc. (ILMN)

Piedmont Investment Advisors Inc. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.0% during the first quarter, HoldingsChannel reports. The firm owned 20,662 shares of the life sciences company’s stock after buying an additional 211 shares during the period. Piedmont Investment Advisors Inc.’s holdings in Illumina were worth $6,419,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Massmutual Trust Co. FSB ADV increased its stake in Illumina by 83.0% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 39 shares during the last quarter. Strategy Asset Managers LLC bought a new position in Illumina in the 1st quarter worth about $26,000. Financial Advocates Investment Management increased its stake in Illumina by 1,430.0% in the 4th quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 572 shares during the last quarter. Proficio Capital Partners LLC increased its stake in Illumina by 61.7% in the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Finally, C J Advisory Inc bought a new position in Illumina in the 1st quarter worth about $29,000. 90.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of Illumina stock opened at $312.83 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. The stock has a market cap of $45.05 billion, a PE ratio of 54.69, a PEG ratio of 2.13 and a beta of 1.15. Illumina, Inc. has a 12 month low of $261.61 and a 12 month high of $372.61.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. The firm had revenue of $846.00 million for the quarter, compared to analyst estimates of $838.70 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The company’s revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.45 EPS. Research analysts forecast that Illumina, Inc. will post 6.68 EPS for the current year.

In other news, SVP Aimee L. Hoyt sold 298 shares of the stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $304.63, for a total transaction of $90,779.74. Following the transaction, the senior vice president now directly owns 2,297 shares in the company, valued at approximately $699,735.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $300.00, for a total value of $990,000.00. Following the transaction, the director now owns 341,568 shares in the company, valued at $102,470,400. The disclosure for this sale can be found here. Insiders have sold a total of 50,329 shares of company stock worth $15,648,675 over the last quarter. Corporate insiders own 0.38% of the company’s stock.

A number of equities analysts have weighed in on the company. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $355.00 target price on the stock in a research note on Tuesday, April 2nd. OTR Global lowered Illumina to a “positive” rating in a research note on Tuesday, April 2nd. Bank of America restated a “buy” rating and issued a $355.00 target price on shares of Illumina in a research note on Wednesday, January 30th. Finally, Deutsche Bank lowered Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price on the stock. in a research note on Friday, January 25th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $353.58.

ILLEGAL ACTIVITY NOTICE: This article was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/23/piedmont-investment-advisors-inc-buys-211-shares-of-illumina-inc-ilmn.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: Retained Earnings

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.